Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study Strengthens Evidence of Link Between Liver Cancer and Diabetes

March 2, 2005
By James L. Abbruzzese, MD, FACP
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 14 No 3
Volume 14
Issue 3

This special “annual highlights” supplement to Oncology News International (ONI)is a compilation of selected news on important advances in the management ofgastrointestinal cancers over the past year, as reported in ONI. Guest Editor, Dr.James L. Abbruzzese, comments on the reports included herein and discussesdevelopments in the clinical management of GI cancers, with a look at the impactof targeted agents with cytotoxic chemotherapy, first-line and adjuvant therapies foradvanced disease, and the role of statins and COX-2 inhibitors in prevention.

SEATTLE-Diabetics may facethree times the risk of liver cancer,according to data from a new study. Anumber of epidemiological studieshave "suggested a relationship betweensome cancer types and diabetes, andthe most consistent results have beenfor cancers of the liver and the pancreas,"said Marie-Claude Rousseau, PhD,a postdoctoral fellow, in the Departmentof Social and Preventive Medicine,at the University of MontrealFaculty of Medicine."Some biological mechanisms havebeen proposed to suggest how diabetesaffects the risk of cancer, but to thisday, they remain only hypothetical. Soclearly, the question of whether cancerrisk is associated with diabetes isstill open," Dr. Rousseau said. Shepresented the findings at the AmericanAssociation for Cancer ResearchThird Annual International Conferenceon Frontiers in Cancer PreventionResearch (abstract 195).The investigators used data collectedfrom a study conducted in Montreal during the 1980s designed to addressworkplace factors and the risk ofcancer among men. The large population-based multisite case-controlstudy included information about priordiagnosis for diabetes, age at diagnosis,and medication use for diabetes.The study sample was comprisedof 3,288 male patients who had beenrecently diagnosed with cancer and509 healthy controls.Patients with diabetes also providedinformation about their usualheight and weight and lifestyle factors."These are important to consider whenstudying diabetes and cancer risk,"Dr. Rousseau said.The investigative team analyzed theassociation between diabetes and 12different types of cancer. "Out of the20 different cancer types that weredocumented in this study, our analysesfocused on 12 types for which thenumber of patients was large enoughto provide sufficient statistical powerfor the analyses," she explained.Study ResultsAfter adjusting for body mass indexand other covariates, the risk ofliver cancer was found to be elevatedamong men who reported a prior diagnosisof diabetes. The adjusted oddsratio (OR) was 3.1. The proportion ofdiabetics was 24% among liver cancerpatients, while only 8% of controlsreported having diabetes."These estimates were slightly higherwhen we used a more stringent definitionof diabetes," Dr. Rousseau said.This definition included only thosesubjects who were taking medication.The adjusted odds ratio for liver cancerfor this subgroup was 3.9.An association was observed withpancreatic cancer, mostly due to recentlydiagnosed diabetes. "This maysuggest that diabetes was a result of thepancreatic cancer rather than the opposite,"Dr. Rousseau said.The researchers did not observe anyassociation with other cancers studied,including melanoma, non-Hodgkin's lymphoma, and cancers ofthe esophagus, stomach, colon,rectum, lung, prostate, bladder, andkidney."While this was not the first studyto examine the link between cancerand diabetes, key features of our studieswere that we could assess the risk ofseveral different cancer types in thesame population and that the patientswere newly diagnosed," Dr. Rousseausaid. "Also, we had information thatallowed us to adjust for important factors,such as body mass index, smoking,and alcohol consumption. In conclusion,our study is strengthening theevidence of a link between diabetesand liver cancer."Dr. Rousseau's colleagues in thestudy were Jack Siemiatycki, PhD, Universityof Montreal, and Marie-EliseParent, PhD, INRS-Institut Armand-Frappier, Laval, Quebec.

Articles in this issue

Smoking Speeds Progression of Pancreas Ca
Alcohol, Obesity, and Smoking Risk Factors for HCC
Eloxatin Receives FDA Indication for Use in Adjuvant Treatment of Stage III Colon Cancer
Adding Bevacizumab Improves Response to Oxaliplatin Regimens
Capecitabine Promises Convenience, Efficacy in LARC, Five Studies Show
Avastin Enhances FOLFOX Efficacy
Panitumumab, Anti-EGFR MoAb,Promising in Colon Cancer
Oxaliplatin/Gemcitabine Effective in Advanced Pancreatic Cancer
Study Strengthens Evidence of Link Between Liver Cancer and Diabetes
Capecitabine Promises Convenience, Efficacy in LARC, Five Studies Show
Capecitabine Equal to Bolus 5-FU/LV in Adjuvant Therapy for Colon Cancer
Three Adjuvant 5-FU/RT Regimens Are Equally Effective
Single-Agent Cetuximab Active in Patients With Refractory Colon Cancer
XELIRI Shows Promise as First-Line Treatment for Advanced Colorectal Ca
UFT Provides ‘Equivalent’ Survival and Quality of Life to 5-FU in Stage II/III Colorectal Cancer
Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content
Advertisement

Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.

Targeted Therapy First Strategy Reduces Need for Chemotherapy in Newly Diagnosed LBCL

Kristie L. Kahl
December 7th 2025
Article

Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.


Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.


The CR/CR with incomplete bone marrow recovery rate was 12.8% in patients with relapsed/refractory CLL/SLL following zanubrutinib treatment.

What Benefit Does Zanubrutinib Provide in Relapsed/Refractory CLL/SLL?

Kyle Doherty
December 7th 2025
Article

The CR/CR with incomplete bone marrow recovery rate was 12.8% in patients with relapsed/refractory CLL/SLL following zanubrutinib treatment.


Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.


Azacitidine plus venetoclax reduced the risk of progressive disease, persistent disease prompting therapy change, relapse, hospice, or death by 45%.

Azacitidine Plus Venetoclax Improves EFS in Acute Myeloid Leukemia

Jonah Feldman
December 7th 2025
Article

Azacitidine plus venetoclax reduced the risk of progressive disease, persistent disease prompting therapy change, relapse, hospice, or death by 45%.


Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

Gina Mauro
December 7th 2025
Article

The phase 3 EPCORE FL-1 trial showed that adding epcoritamab to R2 delivered superior PFS and response rates for patients with relapsed/refractory FL vs R2 alone.

Related Content
Advertisement

Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.

Targeted Therapy First Strategy Reduces Need for Chemotherapy in Newly Diagnosed LBCL

Kristie L. Kahl
December 7th 2025
Article

Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.


Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.


The CR/CR with incomplete bone marrow recovery rate was 12.8% in patients with relapsed/refractory CLL/SLL following zanubrutinib treatment.

What Benefit Does Zanubrutinib Provide in Relapsed/Refractory CLL/SLL?

Kyle Doherty
December 7th 2025
Article

The CR/CR with incomplete bone marrow recovery rate was 12.8% in patients with relapsed/refractory CLL/SLL following zanubrutinib treatment.


Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.


Azacitidine plus venetoclax reduced the risk of progressive disease, persistent disease prompting therapy change, relapse, hospice, or death by 45%.

Azacitidine Plus Venetoclax Improves EFS in Acute Myeloid Leukemia

Jonah Feldman
December 7th 2025
Article

Azacitidine plus venetoclax reduced the risk of progressive disease, persistent disease prompting therapy change, relapse, hospice, or death by 45%.


Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

Gina Mauro
December 7th 2025
Article

The phase 3 EPCORE FL-1 trial showed that adding epcoritamab to R2 delivered superior PFS and response rates for patients with relapsed/refractory FL vs R2 alone.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.